Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial…
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab,…